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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comgroups, control, TNF-a and pitavastatin group. Cells of TNF-a group were co-incubated
with different concentrations（10mg/L，20mg /L，30mg /L）ofTNF-a for 24h.Cells of
pitavastatin group were ﬁrstly coincubated with 0.01, 0.1, 1mmol/L pitavastatin
respectively for 1h, then coincubated with 30mg/L TNF-a for 24h. VCAM -1 and miR-
126 mRNA were detected by quantitative reverse transcription polymerase chain reac-
tion (RT-PCR) andWestern blotting was used to detect protein expression of VCAM-1.
Results: Both detection methods have showed that TNF-a stimulation signiﬁcantly
induced the mRNA and protein expression of VCAM-1 in HUVECs in a dose-
dependent manner, and miR-126 mRNA expression exhibited a decreasing trend when
cultured with TNF-a. The increase of VCAM-1 mRNA and protein expression
induced by TNF-a was inhibited by pitavastatin in a dose-dependent manner, too.
However, there were no differences of the expression of miR-126 among three groups.
Conclusions: These effects may explain the ability of pitavastatin to reduce the
progression of atherosclerosis and may increase the stability of plaques. The ﬁndings
further suggest that inhibitory effect of pitavastatin on VCAM-1 is not related to miR-
126 but depends on other things.Characteristic
Odds Ratio
(95% CI) p-value
History of Diabetes Mellitus 1.7 (1.3, 2.2) <0.001
History of CHF 1.6 (1.3, 2.1) <0.001
History of prior CABG 0.7 (0.5, 0.9) 0.007
Low BMI < 18 3.3 (1.2, 9.1) 0.024
High BMI > 30 4.3 (1.5, 12.1) 0.006
Pre-PVI Anemia 2 (1.5, 2.5) <0.001
Creatinine Clearance < 30 ml/min 2.5 (1.8, 3.6) <0.001
Critical Limb Ischemia 1.6 (1.2, 2.1) 0.001
Status – Urgent 2.9 (2.2, 3.7) <0.001
Status – Emergent 7.1 (4.4, 11.4) <0.001
Contrast volume (ml) > 3 x Creatinine Clearance (ml/ 1.5 (1.1, 1.9) 0.003Renal Insufﬁciency and Contrast Nephropathy
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Preprocedural Statin Administration Beneﬁt According To Baseline Renal
Function: A MetaLAnalysis Of Randomized Controlled Trials
Daniele Giacoppo1, Davide Capodanno1, Piera Capranzano1, Patrizia Aruta1,
Corrado Tamburino1
1Ferrarotto Hospital, Catania, Italy
Background: Preprocedural statin administration seems to reduce contrast–induced
acute kidney injury (CI–AKI). This beneﬁt, however, might be limited to patients
without advanced chronic kidney disease.
Methods: Randomized controlled trials (RCTs) comparing preprocedural statin
administration before coronary catheterization with standard strategies were searched
in MEDLINE/PubMed, Embase, Scopus, Web of Science, and ScienceDirect data-
bases. Patients were stratiﬁed in two groups according to a glomerular ﬁltration rate
(GFR) < 60 ml/min or  60 ml/min. A DerSimonian-Laird random-effects model was
used. The endpoint, quantiﬁed and reported as pooled risk ratio (RR) with 95%
conﬁdence interval (CI), was the CI–AKI incidence. Heterogeneity was graded using
the I2 statistic.
Results: Eight RCTs were included. A total of 143 patients (8.5%) with baseline
GFR < 60 ml/min and 112 patients (3.6%) with baseline GFR  60 ml/min developed
CI–AKI. In patients with GFR < 60 ml/min (top panel), the pooled RR indicated
a beneﬁt from statin use(RR 0.67, 95% CI 0.45–1.00, p¼0.50). In patients with GFR
 60 ml/min (bottom panel), the pooled RR indicated a highly signiﬁcant greater
beneﬁt (RR 0.40, 95% CI 0.27–0.61, p< 0.0001) from statin use. I2 was modest in the
ﬁrst analysis (27.5%) and absent in the second(0%).B74 JACC Vol 64/11/Suppl B j September 13–17Conclusions: Statins administration before coronary catheterization leads to a sig-
niﬁcant reduction in the pooled RR of CI-AKI in patients with GFR  60 ml/min.
However a reduced but persistent beneﬁt was seen also in patients with GFR < 60 ml/
min. Larger double–blind RCTs are requested to conﬁrm this results.
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Background: We evaluated the prevalence, predictors, and outcomes of patients who
developed contrast induced nephropathy (CIN) after undergoing percutaneous
vascular intervention (PVI). The association between renal function based contrast
dose and CIN was also explored.
Methods: A total of 13,126 PVI patients from 2010 to 2013 were included in the
analysis. Patients on chronic dialysis or those undergoing a PVI and open vascular
surgery procedure in the same setting were excluded. CIN was deﬁned as an increase
in serum creatinine of  0.5 mg/dl above baseline. A CIN risk model was developed
using logistic regression analysis.
Results: CIN occurred in 3% (400 patients) of the cohort and of these 6.5% (26
patients) developed the need for new dialysis. CIN was strongly associated with
adverse outcome including death (OR 40, CI 26-62.1, p < 0.001), myocardial
infarction (MI) (OR 25.8, CI 15.6-42.6, p < 0.001), TIA/stroke (OR 10.3, CI 4.4-24.2,
p < 0.001), vascular access complications (OR 4, CI 2.8-5.7, p < 0.001), and
transfusion (OR 12.6, CI 10.1-15.7, p < 0.001). Hospital stay was longer in patients
who developed CIN vs. those who did not (non-CIN) (median 9 vs. 2 days respec-
tively, p < 0.001, mean 11.6 vs. 3.8 days respectively, p < 0.001). Predictors of CIN
by logistic regression are shown in the table (Area under the ROC Curve (AUC):
0.789).min)Conclusions: CIN is a common complication associated with PVI and strongly
associated with the risk of in-hospital death, MI, stroke, transfusion and increased
hospital length of stay. Clinical predictors of CIN include high and low body weight,
diabetes, heart failure, anemia, baseline renal dysfunction, critical limb ischemia and a
higher acuity of the PVI procedure. Exceeding a contrast dose of greater than three
times the creatinine clearance was strongly associated with CIN, and suggests the need
for minimizing contrast dose in patients undergoing PVI.
TCT-254
Very Low Intravenous Contrast Dose (20cc) Protocol for Computed
Tomography Angiography (CTA) Providing Comprehensive Cardiac and
Vascular Assessment for Transcatheter Aortic Valve Replacement (TAVR) in
Patients with Chronic Kidney Disease (CKD)
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Torsten P. Vahl1, Martin Leon1, Belinda Dsouza1
1Columbia University Medical Center, New York, NY
Background: TAVR is a lifesaving procedure for many patients at high risk for
surgical aortic valve replacement. The prevalence of CKD and risk for contrast-
induced nephropathy in this population is high. A very low contrast dose CTA pro-
tocol enabling comprehensive cardiac and vascular imaging would be valuable in this
fragile patient population., 2014 j TCT Abstracts/Renal Insufﬁciency and Contrast Nephropathy
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMMethods: All patients with severe symptomatic aortic stenosis, CKD (est CrCl<
30mL/min) and BMI< 40kg/m2 undergoing pre-TAVR CTA assessment from 2013-4
at Columbia University Medical Center using the novel protocol were included. Using
a 320-slice volumetric scanner (Aquilion One, Toshiba America Medical Systems),
the protocol included ECG-gated volume scanning of the aortic root followed by
ultrahelical vascular scanning from the aortic arch through femoral arteries, both using
the same 20cc contrast bolus injection. 2 experienced, blinded cardiologists performed
annular and aortic anatomic measurements; agreement was determined using intra-
class correlation coefﬁcient. 2 experienced, blinded radiologists graded image quality
for assessing ileofemoral vascular access on a 4-point scale (1 nondiagnostic; 2
diagnostic but limited; 3 good, mild limitations; 4 excellent); agreement was deter-
mined using weighted kappa.
Results: 19 patients (mean age 83, BMI 24 kg/m2; 53% women) were studied. There
was excellent intra and interobserver agreement for cardiac anatomic measurements
(Table). The average vascular access score was 2.6; both radiologists found diagnostic
quality vascular imaging in 100% of cases with outstanding inter-radiologist agree-
ment (k¼0.91).
Conclusions: This study is the largest of its kind to report the feasibility and
reproducibility of measurements, for a very low contrast dose protocol for
comprehensive pre-TAVR CTA. There was excellent agreement of cardiac mea-
surements and all studies were assessed as diagnostic quality for vascular access
assessment.Table 1. Comparison of Observer Agreement of Measurements Using a Very
Low Contrast Dose Cardiac CTA Protocol
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0.998 0.994 0.92 0.92 0.97 0.98
Interobserver
Agreement
0.996 0.995 0.96 0.96 0.82 0.88 0.91TCT-255
Effectiveness Of Preprocedural Statin Administration In Reducing
ContrastLInduced Acute Kidney Injury: A MetaLAnalysis Of Randomized
Controlled Trials
Daniele Giacoppo1, Davide Capodanno1, Piera Capranzano1, Patrizia Aruta1,
Corrado Tamburino1
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Background: Preprocedural statin administration might reduce contrast–induced
acute kidney injury (CI–AKI) incidence but current evidence is controversial.
Methods: Randomized controlled trials (RCTs) comparing preprocedural statin
administration before coronary catheterization with standard strategy (hydration alone
or plus Nacetylcysteine) were searched in MEDLINE/PubMed, Embase, Scopus,
Cochrane Library, Web of Science, and ScienceDirect electronic databases. No lan-
guage limitations, ﬁlters or publication date restrictions were applied. A DerSimonian-
Laird random-effects model was used. The endpoint measure, quantiﬁed and reported
as pooled risk ratio (RR) with 95% conﬁdence interval (CI), was CI–AKI incidence.
The inﬂuence of removal of 1 study each time on RR was measured to establish the
impact of individual trials on the pooled effect size. Heterogeneity was graded using
the I2 statistic.
Results: A total of 8 RCTs were included (n¼4984). The incidence of CI-AKI was
3.9% in the statin group (n¼2480) and 7.0% in the control group (n¼2504). In the
pooled analysis patients receiving statins had 46% lower relative risk (RR) of CI-
AKI compared with the control group (RR: 0.54, 95% CI 0.38-0.78, p¼0.001). A
moderate degree of non-signiﬁcant heterogeneity was present (c2¼12.500,
p¼0.099, I2¼ 41.9%, s2¼0.100). The relative weight of each study on the pooled
RR was estimated.Conclusions: Statins administration before coronary angiography or percutaneous
coronary intervention leads to a signiﬁcant risk reduction of CI-AKI development.
Larger double–blind RCTs are requested to conﬁrm this promising results.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/ReTCT-256
Beneﬁt of Statin Pretreatment in Prevention of Contrast Induced Nephropathy:
Systematic Review and Meta-analysis
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Prakash Suryanarayana1, Tom Lassar1, Kwan S. Lee1
1University of Arizona, Tucson, AZ, 2Mayo Clinic, Scottsdale, AZ
Background: Previous studies have suggested that statin pre-treatment prevents
contrast-induced nephropathy (CIN). This meta-analysis aims to assess the role of
statin use in CIN prevention, as well as to determine patient subgroups that will beneﬁt
from statin pre-treatment.
Methods:We searched 843 potentially relevant citations from PubMed, EMBASE,Web
of science and the Cochrane Central Register of Controlled Trials databases for ran-
domized controlled trials (RCT) comparing statin pre-treatment versus placebo for pre-
venting CIN. From this, 9 randomized trials met our inclusion criteria. The primary
endpoint was the incidence of CIN within 2-5 days after contrast administration. Random
effects model was used with Mantel-Haenszel Risk ratio as a summary effect size.
Results: Data analyzed from nine randomized studies with a total of 5,143 patients,
where 2,559 received statins and 2,584 received placebo, showed that statin pre-
treatment was associated with signiﬁcant reduction in risk of CIN (MH-RR¼0.47,
95% CI: 0.34-0.64, Z¼4.49, p< 0.00001). This beneﬁcial effect of statins was also
seen in patients with baseline renal impairment (RR-MH¼0.46, 95% CI: 0.29-0.72,
p¼0.0008) and those who were co-treated with NAC (RR-MH¼0.46, 95% CI: 0.25-
0.83, p¼0.01).Conclusions: Statin pre-treatment leads to signiﬁcant reduction in CIN, and should be
strongly considered in all patients who are planned for diagnostic and interventional
procedures involving contrast-media administration.
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Background: There have been conﬂicting results across the trials that evaluated
prophylactic efﬁcacy of short-term high-dose statin pre-treatment for prevention of
CIN in patients undergoing coronary angiography (CAG). We perform an up-to-date
meta-analysis regarding the efﬁcacy of high-dose statin pre-treatment in preventing
post-procedural incidence of contrast-induced nephropathy (CIN).
Methods: PubMed, EMBASE, BioMed Central, Cochrane Central Register of
Controlled Trials were searched to February 2014. Randomized controlled trials
(RCTs) comparing high-dose statin versus low-dose statin or placebo pre-treatment for
prevention of CIN in patients undergoing CAG were included. The primary endpoint
was the incidence of CIN within 2-5days after CAG. The relative risk (RR) with 95%
CI was the effect measure.
Results: This analysis included 13 RCTs with 5,825 total patients; about half of them
(n¼2,889) were pre-treated with high-dose statin (at least 40mg of atorvastatin) before
CAG, and the remainders (n¼2,936) pretreated with low-dose statin or placebo. In
random-effect model, high-dose statin pre-treatment signiﬁcantly reduced the inci-
dence of CIN (RR 0.45, 95% CI 0.35-0.57, p< 0.001, I2¼8.2%, NNT 16), compared
with low-dose statin or placebo. The beneﬁt of high-dose statin was consistent in both
comparison with low-dose statin (RR 0.47, 95% CI 0.34-0.65, p< 0.001, I2¼28.4%,
NNT 19) or placebo (RR 0.34, 95% CI 0.21-0.58, p< 0.001, I2¼0.0%, NNT 16). In
addition, high-dose statin showed signiﬁcant reduction of CIN across various sub-
groups of chronic kidney disease, acute coronary syndrome, and old age (60years),
regardless of osmolarity of contrast or administration of N-acetylcystein.
Conclusions: High-dose statin pre-treatment signiﬁcantly reduced the incidence of
CIN in patients undergoing CAG. Considering prognostic importance of CIN and
clear beneﬁcial effect of statin in this meta-analysis, high-dose statin pre-treatment
may be more actively employed as an effective prophylactic measure to prevent CIN.nal Insufﬁciency and Contrast Nephropathy B75
